Democrats could make drug pricing deal with President Trump
Many midterm winners campaigned on bringing down prices, and experts predict the issue to remain top of mind.
Regulatory
How the pharma industry may be impacted by drug pricing and other policies in 2019
Now that the political climate lends itself to action on drug pricing, the days of pharma nirvana may be coming to an end. Here’s a look at the policy considerations likely to vex the industry in the year ahead.
Karen Newmark named Point of Care Communications Council executive director
Newmark said she is prioritizing working with industry stakeholders on verification and validation standards.
Democratic senator: Constituents want bipartisanship, healthcare transparency
Sen. Christopher Coons (D-DE) talked healthcare priorities at the Coalition for Healthcare Communication post-election conference in Washington D.C. on Monday.
Brodeur Partners’ Lauren Levinson on transparency in healthcare proposals
With greater transparency of the cost and sale price of a drug must also come greater transparency of the inputs, ecosystem, and risk investment on which drug development relies.
Industry, government square off over list prices in DTC ads
The pharma industry is set for a battle as the Trump administration and trade group PhRMA offer competing solutions to putting drug prices in TV ads.
Gilead names Michael Boyd VP of government affairs, policy
Boyd has worked at AbbVie, Pfizer, and Schering-Plough.
4 expert takes on what the midterms mean for pharma
MM&M asked experts to predict what the next two years could hold for pharma- and healthcare-related legislation.
These 5 companies have the most at stake if drug prices are based on international averages
The Trump administration has proposed basing Medicare Part B drug prices on what other countries pay.
Trump orders drug companies to disclose list prices in DTC ads. Will it actually happen?
PhRMA pushed back on the HHS plan for disclosing drug prices in ads, putting itself in Trump’s Twitter crosshairs, but experts say flaws in the plan could impede its rollout anyway.
Want to read more?
Please login or register first to view this content.
